Valuation: Regeneron Pharmaceuticals, Inc.

Market Cap 75.81B 65.83B 61.38B 56.38B 107B 7,212B 108B 724B 283B 3,605B 285B 278B 11,945B P/E 2026 *
17.7x
P/E 2027 * 15.1x
Enterprise Value 68.95B 59.87B 55.82B 51.28B 96.98B 6,558B 98.04B 658B 257B 3,278B 259B 253B 10,863B EV / Sales 2026 *
4.08x
EV / Sales 2027 * 3.56x
Free-Float
71.07%
Yield 2026 *
0.51%
Yield 2027 * 0.58%
1 day+0.19%
1 week+9.42%
Current month-0.26%
1 month+17.06%
3 months+7.25%
6 months-1.86%
Current year-1.45%
1 week 691
Extreme 691
772.75
1 month 637.72
Extreme 637.715
772.75
Current year 591.52
Extreme 591.52
821.11
1 year 541
Extreme 541
821.11
3 years 476.49
Extreme 476.4869
1,211.2
5 years 476.49
Extreme 476.4869
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
Manager TitleAgeSince
President 66 01/01/2001
Chief Executive Officer 73 08/01/1988
Director of Finance/CFO 55 05/02/2024
Director TitleAgeSince
Chairman 73 09/06/2023
Director/Board Member 85 01/06/1991
Director/Board Member 85 01/06/1991
Date Insider Type Main position Quantity % Market Cap.
2/7/26 Sell

Director

-200 0.0002%
19/2/26 Fiscal year

Director

4,914 0.0048%
9/2/26 Fiscal year

SVP Controller

4,036 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
+0.19%+9.42%+33.09%-0.75% 75.81B
+0.86%-9.15%+20.80%+181.80% 48.57B
+3.72%-4.47%-7.16%+18.96% 46.01B
+3.64%+10.69%-51.21%-51.75% 41.66B
+3.29%+1.38%+57.68%-22.49% 29.82B
+1.83%-7.18%+54.54%+89.53% 24.01B
+3.36%+2.12%+106.19%-47.32% 22.01B
+0.81%-2.97%-6.77%+164.33% 19.09B
+0.05%-5.99%+64.98%+113.20% 15.83B
+2.64%-4.07%+71.87%+162.62% 15.63B
Average +2.12%-0.47%+34.40%+60.81% 33.84B
Weighted average by Cap. +1.98%+1.74%+24.95%+45.49%

Financials

2026 *2027 *
Net sales 16.89B 14.66B 13.67B 12.56B 23.75B 1,606B 24.02B 161B 63.01B 803B 63.42B 62.03B 2,661B 18.34B 15.92B 14.85B 13.64B 25.8B 1,745B 26.08B 175B 68.43B 872B 68.87B 67.36B 2,890B
Net income 4.61B 4B 3.73B 3.43B 6.48B 438B 6.55B 43.97B 17.19B 219B 17.3B 16.92B 726B 5.35B 4.65B 4.33B 3.98B 7.53B 509B 7.61B 51.09B 19.97B 255B 20.1B 19.66B 843B
Net Debt -6.87B -5.96B -5.56B -5.11B -9.66B -653B -9.77B -65.56B -25.63B -327B -25.79B -25.23B -1,082B -10.55B -9.16B -8.54B -7.85B -14.84B -1,004B -15.01B -101B -39.38B -502B -39.63B -38.76B -1,663B
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,410
Date Price Change Volume
05/08/26 USD 760.66 +0.19% 804,434
03/08/26 USD 759.24 -0.44% 842,730
31/07/26 USD 762.63 +3.29% 1,158,583
30/07/26 USD 738.34 +6.17% 1,460,963
29/07/26 USD 695.42 +0.03% 1,022,421
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
759.24USD
Average target price
833.54USD
Spread / Average Target
+9.79%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. REGN Stock